

Original Research Article

Acute and subchronic toxicities of the aqueous extract of the *Hymenocardia acida* roots in rodents

ABSTRACT

The roots of *Hymenocardia acida* are used in traditional African medicine to treat mainly erectile dysfunction. This study aims to evaluate the acute and subchronic toxicities of the aqueous extract of *Hymenocardia acida* roots in rodents. The acute intraperitoneal and oral toxicities of the extract were determined by the method of Miller and Tainter. Subchronic oral toxicity with doses of 500 and 1000 mg/kg body weight was assessed according to the slightly modified OECD 408 method. The results showed that the 50% intraperitoneal lethal dose was 223.87 mg/kg body weight in mice. In addition, the 50% oral lethal dose in mice was greater than 12,000 mg/kg body weight. In the subchronic study, the extract induced a significant ($P < .001$) increase in white blood cell count at 1000 mg/kg body weight after 60 days of treatment. From the thirtieth day of treatment onwards, the extract induced a significant ($P < .05$) reduction in blood glucose levels at the 500 mg/kg body weight dose and a significant ($P < .05$) increase in blood glucose levels at the 1000 mg/kg body weight Pleasdose. Aqueous extract of *Hymenocardia acida* roots is toxic by the intraperitoneal route and exerts a non-specific immunity action at high doses. However, it may have protective effects on the liver and cardiovascular system.

Keywords: *Hymenocardia acida*, acute toxicity, subchronic toxicity

1. INTRODUCTION

In recent years there has been a renewed interest in herbal medicine. Indeed, more and more people are using herbal medicines to treat themselves [1]. It should be noted that the traditional use of any plant for therapeutic purposes does not guarantee its safety [2]. While the pharmacological effects of many plants have been proven in various laboratories, their toxicity is generally unknown. Therefore, toxicity assessment of herbal preparations is important in determining the safety of these remedies.

Hymenocardia acida (Euphorbiaceae) is a dioecious, deciduous shrub, reaching 6-10 m in height, with smooth, light brown or grey bark [3]. It is a savannah species, common in northern Côte d'Ivoire and Burkina Faso, whose range extends well beyond West Africa to Uganda [4]. In powder or paste form, the bark is ingested to treat abdominal pain, diarrhoea, dysentery, menstrual pain, female sterility, painful swellings, coughs and epileptic fits [5]. Chemical studies on *H. acida* have revealed the presence of alkaloid, anthocyanin, anthraquinones, carbohydrates, glycoside, cardiac, flavonoids, phenols, saponins, steroids, tannins and [6,7]

The present study aims to evaluate the acute and subchronic toxicities of the aqueous extract of *H. acida* roots in rodents.

2. MATERIALS AND METHODS

2.1 Experimental Animals

Comment [G1]: This statement is confusing. Please state and explain in a simple sentences and understandable reader

Comment [G2]:

Comment [G3]: Please state the important data of results, then state a brief conclusion Thank you

Comment [G4]: The conclusion is not concluded from the result statement. Please revised. Thank you

Mice of the species *Mus musculus*, Swiss strain, 8 weeks old and weighing between 20 and 30 g were used for the acute toxicity experiments. Rats of the species *Rattus norvegicus*, Wistar strain, aged 8 weeks and weighing between 80 and 100 g were used for the subchronic toxicity test. These animals (males and females) came from the vivarium of the Ecole Normale Supérieure (Abidjan, Cote d'Ivoire). In this vivarium, the average temperature is 28 ± 2 °C with a relative humidity of 60% and a photoperiod of 12/12. The animals were fed with a standard diet for experimental animals and received water ad libitum.

2.2 Plant material

The roots of *H. acida* were collected in Korhogo in the Poro region (Cote d'Ivoire). They were chosen because they are traditionally used by the local population to treat erectile dysfunction. A sample of this plant was identified at the National Floristic Center of the University of Félix HOUPHOUËT-BOIGNY (Abidjan, Cote d'Ivoire).

2.3 Preparation of the aqueous extract

The roots of *H. acida* were cut into small pieces and dried in a room at room temperature (28-30°C). Three hundred g (300 g) of *H. acida* root were boiled in 1000 mL of distilled water for 30 min in a glass vessel. After cooling and filtration through cotton wool and Wattman paper, the resulting decoctate was freeze-dried. The powder obtained after freeze-drying constitutes the aqueous extract of *H. acida* roots (AEHA).

2.4 Acute toxicity study

2.4.1 Acute intraperitoneal toxicity

Acute toxicity by intraperitoneal injection was performed with 30 mice divided into 5 groups of 6 subjects (male and female) each. Four groups were treated with increasing doses of AEHA ranging from 100 to 400 mg/kg body weight (BW). The control were given saline (NaCl 9‰). The mortality rate was recorded for each dose used. A dose-lethality curve representing the percentages of mortality versus the logarithms of the doses was plotted [8].

2.4.2 Acute oral toxicity

Acute oral toxicity was performed with 30 mice divided into 6 groups of 5 animals each. Five groups were treated with increasing doses of AEHA ranging from 2000 to 12000 mg/kg BW. The control received distilled water. Mortality, morbidity and weight change were recorded over 14 days [8].

2.5 Subchronic toxicity study

Subchronic oral toxicity was assessed according to the Organisation for Economic Co-operation and Development 408 method, slightly modified [9]. Forty-eight (48) adult rats were divided into 3 groups of 16 animals each. Each group contained an equal number of males and females and was treated as follows:

- Group 1: control, receiving distilled water;
- Group 2: treated, receiving 500 mg/kg BW of AEHA;
- Group 3: treated, receiving 1000 mg/kg BW of AEHA.

The animals received a daily volume of 1 mL of either distilled water or extract per route. The animals were weighed weekly. On days 30 and 60 of treatment, 24 subjects (4 males and 4 females) were randomly selected from each group and sacrificed by decapitation. The blood was collected for the determination of hematological and biochemical parameters. The liver,

lungs, heart and kidneys were removed, weighed immediately and fixed in 10% formalin for histopathological study.

2.6 Determination of biochemical and hematological parameters

Blood glucose, uric acid and triglycerides were determined by enzymatic tests [10,11]. Total cholesterol was determined by the enzymatic test of Allain et al. [12]. Urea was determined by a kinetic assay in which the onset of the reaction is linear within a defined time interval [13]. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine were determined by colorimetric methods [14,15,16]. The determination of white blood cells, red blood cells, platelets and haematocrit was performed according to the standard methods of Baker et al. [17].

2.7 Histopathological study

The histopathological study was performed according to the method described by Lamb [18]. Organs were preserved in 10% formalin for 48 hours and cut to a thickness of 4 μ m using a microtome after embedding in paraffin. The organs were then stained with hematoxylin-eosin, fixed between slide and coverslip before being observed using a camera microscope.

2.8 Statistical analysis

Statistical analysis of the experimental results was performed using GraphPad Prism 5.01 (USA). The values are presented as mean $\pm$ standard error (M $\pm$ SEM). The data were evaluated by the one-way ANOVA method of analysis followed by Tukey's multiple comparison test at the 5% threshold to assess the significance of the observed differences.

3. RESULTS

3.1 Acute intraperitoneal toxicity

Intraperitoneal administration of AEHA caused a decrease in mobility and an increase in drowsiness time in mice. The first deaths occurred 1 hour after treatment. The 50 % Lethal Dose (LD50) value of AEHA in mice by the intraperitoneal route is 223.87 mg/kg BW (Fig 1)

3.2 Acute oral toxicity

Fig 1 Oral administration of AEHA did not result in death in mice. The oral LD50 of AEHA in mice is therefore greater than 12,000 mg/kg BW.




Figure 1: Dose-fatality curve after intraperitoneal injection of AEHA to mice

3.3 Subchronic toxicity

3.3.1 Effect of AEHA on the evolution of the body weight of animals

During treatment, the body weights of the rats increased progressively with time. The body weight gain of animals treated with 500 and 1000 mg/kg BW of AEHA was approximately the same and there was no significant difference between the treated and the control (Figs 2 and 3).




Figure 2. Effect of different doses of AEHA administration on the body weight of males after 60 days treatment.

Data are presented as mean $\pm$ SEM (n = 8)




Figure 3. Effect of different doses of AEHA administration on the body weight of females after 60 days treatment. Data are presented as mean $\pm$ SEM (n = 8).

3.3.2 Effect of AEHA on vital organ weights of animals

After 30 days of treatment with AEHA, the results showed no significant change in the weights of kidney, heart, liver and lung in the animals compared to the controls. However, after 60 days of treatment with AEHA, there was a significant ($P < .05$) increase in heart weight in females at 500 and 1000 mg/kg BW compared to control. Also there was a significant increase ($P < .05$) in kidney weight in females at 500 mg/kg BW compared to control. Then, the results showed respectively a significant increase in lung weight in females at 500 ($P < .05$) and 1000 mg/kg BW ($P < .01$) compared to control and no significant variation in treated males compared to control. Finally no significant variation in liver weight in males and females compared to controls on day 60 of AEHA treatment was revealed. (Table I).

Table I. Effect of different doses of AEHA administration on vital organs of animals after 60 days treatment.

		Treatment (60 days)		
Vital organs (g/100g BW)		Control	AEHA ₅₀₀	AEHA ₁₀₀₀
Heart	Male	0,35 $\pm$ 0,01	0,31 $\pm$ 0,01	0,33 $\pm$ 0,01
	Female	0,30 $\pm$ 0,02	0,38 $\pm$ 0,01 *	0,37 $\pm$ 0,01 *
Liver	Male	2,82 $\pm$ 0,13	2,76 $\pm$ 0,11	3,12 $\pm$ 0,12
	Female	3,01 $\pm$ 0,08	3,47 $\pm$ 0,15	3,35 $\pm$ 0,15
Kidney	Male	0,94 $\pm$ 0,04	0,96 $\pm$ 0,04	0,94 $\pm$ 0,06
	Female	0,45 $\pm$ 0,02	0,55 $\pm$ 0,02 *	0,56 $\pm$ 0,03
Lung	Male	0,97 $\pm$ 0,12	0,76 $\pm$ 0,08	0,95 $\pm$ 0,05
	Female	0,60 $\pm$ 0,02	0,73 $\pm$ 0,05 *	0,85 $\pm$ 0,0 **1

Data are presented as mean $\pm$ SEM (n = 8). * $P < .05$, ** $P < .01$

3.3.3 Effects of AEHA on hematological parameters in animals

Administration of AEHA induced a significant ($P < .05$) increase in white blood cell count at 500 mg/kg BW in females and at 1000 mg/kg BW ($P < .001$) in males and females after 30 days of treatment. For blood platelets, AEHA treatment resulted in a significant decrease ($P < .05$) at 1000 mg/kg BW after 30 days of treatment. Red blood cells, hematocrit, and hemoglobin did not change significantly in animals after 30 and 60 days of AEHA treatment compared to controls (Table II and III).

Table II. Effect of different doses of AEHA administration on the white blood cell, red blood cell, hemoglobin, hematocrit, blood platelet of animals after 30 days treatment.

		Treatment (30 days)		
		Control	AEHA ₅₀₀	AEHA ₁₀₀₀
WBC ($\times 10^3 \mu\text{L}^{-1}$)	Male	21,98 $\pm$ 1,41	23,64 $\pm$ 0,7	40 $\pm$ 0,9 ***
	Female	5,48 $\pm$ 0,54	7,84 $\pm$ 0,76 *	13,4 $\pm$ 0,5 ***
RBC ($\times 10^6 \mu\text{L}^{-1}$)	Male	6,61 $\pm$ 0,11	6,94 $\pm$ 0,2	7,15 $\pm$ 0,13
	Female	6,38 $\pm$ 0,20	6,94 $\pm$ 0,3	6,38 $\pm$ 0,59
HGB (g/dL)	Male	10,93 $\pm$ 0,55	11,60 $\pm$ 0,15	12,27 $\pm$ 0,29
	Female	11,58 $\pm$ 0,46	11,97 $\pm$ 0,52	11,13 $\pm$ 0,67
HCT (%)	Male	36,20 $\pm$ 2,85	39,43 $\pm$ 0,90	41,13 $\pm$ 1,88
	Female	42,57 $\pm$ 2,17	40,17 $\pm$ 1,91	37,33 $\pm$ 2,26
PLT ($\times 10^3 \mu\text{L}^{-1}$)	Male	857 $\pm$ 57	1323 $\pm$ 149	785 $\pm$ 91
	Female	662 $\pm$ 12	661 $\pm$ 6	616 $\pm$ 3 *

Data are presented as mean $\pm$ SEM (n = 8). * $P < .05$, ** $P < .01$, *** $P < .001$

Table III. Effect of different doses of AEHA administration on the white blood cell, red blood cell, hemoglobin, hematocrit, blood platelet of animals after 60 days treatment.

		Treatment (60 days)		
		Control	AEHA ₅₀₀	AEHA ₁₀₀₀
WBC ($\times 10^3 \mu\text{L}^{-1}$)	Male	24,00 $\pm$ 2,08	21,30 $\pm$ 0,64	23,73 $\pm$ 0,86
	Female	12,87 $\pm$ 0,8	14,4 $\pm$ 0,8	11,67 $\pm$ 0,29
RBC ($\times 10^6 \mu\text{L}^{-1}$)	Male	8,32 $\pm$ 0,10	8,44 $\pm$ 0,22	8,42 $\pm$ 0,41
	Female	7,66 $\pm$ 0,33	8,05 $\pm$ 0,08	8,01 $\pm$ 0,15
HGB (g/dL)	Male	13,77 $\pm$ 0,12	14,23 $\pm$ 0,32	13,73 $\pm$ 0,52
	Female	13,40 $\pm$ 0,96	13,90 $\pm$ 0,32	13,17 $\pm$ 0,41
HCT (%)	Male	45,73 $\pm$ 0,03	46,20 $\pm$ 1,51	45,17 $\pm$ 2,17
	Female	45,90 $\pm$ 1,00	45,97 $\pm$ 0,28	41,93 $\pm$ 2,04
PLT ($\times 10^3 \mu\text{L}^{-1}$)	Male	996 $\pm$ 84	950 $\pm$ 82	875 $\pm$ 47
	Female	795 $\pm$ 2	826 $\pm$ 20	762 $\pm$ 5

Data are presented as mean $\pm$ SEM (n = 8). * $P < .05$

3.3.4 Effects of AEHA on serum glucose and lipid concentration

The blood glucose and lipid values of the animals after 30 and 60 days of treatment with AEHA are shown in Table IV. The extract induced after 30 and 60 days of treatment a significant decrease ($P < .05$) in glucose level at 500 mg/kg BW and a significant increase ($P < .05$) in glucose level at 1000 mg/kg BW in males compared to control; On the other hand in females no significant variation was observed compared to controls. On the 30th day of treatment there was a significant increase ($P < .01$) at 500 and 1000 mg/kg BW in triglycerid level in males compared to control. Also a significant ($P < .05$) increase in triglycerid level is observed at 500 mg/kg BW in females compared to control. At day 60, a significant ($P < .05$) increase in triglyceride level at 1000 mg/kg BW was observed in females compared to control. After 60 days of treatment there was a significant ($P < .01$) decrease in cholesterol level at 1000 mg/kg BW in males compared to control.

Table IV. Effect of different doses of AEHA administration on serum concentrations of Glucose, Triglycerid and total cholesterol of animals

Duration of treatment	Doses (mg/Kg BW)		Glucose (g/L)	Triglycerid g/L)	Total cholesterol (g/L)
30 days	Control	Male	1,15 +/- 0,04	0,80 +/- 0,10	0,76 +/- 0,01
		Female	1,01 +/- 0,061	0,71 +/- 0,02	0,74 +/- 0,04
	AEHA ₅₀₀	Male	0,97 +/- 0,01**	0,83 +/- 0,03	0,75 +/- 0,01
		Female	0,87 +/- 0,09	0,85 +/- 0,02*	0,85 +/- 0,02
	AEHA ₁₀₀₀	Male	1,27 +/- 0,03*	0,79 +/- 0,04	0,75 +/- 0,01
		Female	0,91 +/- 0,04	0,76 +/- 0,03	0,82 +/- 0,01
60 days	Control	Male	1,09 +/- 0,014	0,74 +/- 0,02	0,77 +/- 0,01
		Female	0,90 +/- 0,06	0,58 +/- 0,07	0,66 +/- 0,07
	AEHA ₅₀₀	Male	0,87 +/- 0,02***	0,73 +/- 0,01	0,75 +/- 0,03
		Female	0,89 +/- 0,05	0,45 +/- 0,01	0,78 +/- 0,01
	AEHA ₁₀₀₀	Male	1,19 +/- 0,03**	0,75 +/- 0,02	0,61 +/- 0,03**
		Female	0,96 +/- 0,05	0,77 +/- 0,03*	0,74 +/- 0,03

Data are presented as mean +/- SEM (n = 8). * $P < .05$, ** $P < .01$, *** $P < .001$

3.3.5 Effects of AEHA on serum concentration of renal parameters

There were no significant changes in serum urea, uric acid and creatinine at 500 and 1000 mg/kg BW in males and females compared to controls.

3.3.6 Effects of AEHA on serum concentration of liver parameters

The results of liver parameter analyses after 30 and 60 days of treatment with AEHA are shown in Table V. A significant increase ($P < .01$) in total protein level at 500 mg/kg BW in males after 60 days of treatment compared to controls was observed. The other hepatic parameters (AST, ALT) did not change significantly at 500 and 1000 mg/kg BW in males and females.

Comment [G5]: Please present the data. Thank you

Table V. Effect of different doses of AEHA administration on serum concentrations of AST, ALT and total protein of animals

Duration of treatment	Doses (mg/Kg BW)		AST (UI/L)	ALT (UI/L)	Total Protein (g/L)
30 days	Control	Male	256,0 +/- 2,08	71,00 +/- 6,11	66,00 +/- 2,52
		Female	219,3 +/- 27,8	60,33 +/- 6,01	68,67 +/- 1,20
	AEHA ₅₀₀	Male	244,7 +/- 12,91	60,67 +/- 2,18	67,67 +/- 0,88
		Female	280,3 +/- 12,5	63,33 +/- 4,09	68,00 +/- 2,51
	AEHA ₁₀₀₀	Male	275,0 +/- 17,56	65,00 +/- 2,51	68,00 +/- 0,58
		Female	195,0 +/- 14,5	59,33 +/- 1,85	68,67 +/- 0,88
60 days	Control	Male	241,3 +/- 16,48	36,00 +/- 1,53	71,33 +/- 0,33
		Female	247,3 +/- 12,3	41,33 +/- 0,33	74,33 +/- 2,33
	AEHA ₅₀₀	Male	257,7 +/- 11,78	39,00 +/- 1,53	77,00 +/- 0,58**
		Female	254,3 +/- 37,5	43,67 +/- 1,85	76,00 +/- 0,57
	AEHA ₁₀₀₀	Male	294,3 +/- 53,25	41,67 +/- 3,28	72,67 +/- 0,88
		Female	191,3 +/- 10,8	37,00 +/- 1,00	75,00 +/- 2,08

Data are presented as mean +/- SEM (n = 8). * $P < .05$

3.3.7 Effects of AEHA on the histological structure of the liver and kidney

Histopathological examination of the liver revealed no apparent signs of inflammation or hepatic cell necrosis in either control or treated rats (Fig 4). Furthermore, there was no significant difference between the kidneys of treated and control rats (Fig 5).




Figure 4: Micrographs of liver of control and 1000 mg/Kg BW of AEHA-treated rats after 60 days treatment.

A₁: Female control; A₂: Male control; B₁: Female Treated 1000 mg/kg BW; B₂: Male Treated 1000 mg/kg BW; Magnification: ×400; Hematoxylin and Eosin staining




Figure 5: Micrographs of kidney of control and 1000 mg/Kg BW of AEHA-treated rats after 60 days treatment.

A₁: Female control; A₂: Male control; B₁: Female Treated 1000 mg/kg BW; B₂: Male Treated 1000 mg/kg BW; Magnification: ×400; Hematoxylin and Eosin staining

4. DISCUSSION

Substances with an LD₅₀ between 50 and 500 mg/kg BW are toxic and those with an LD₅₀ above 5000 mg/kg BW are practically non-toxic [19]. According to this classification, AEHA is intraperitoneally toxic and not orally toxic. It is known from the literature that the toxicity of a substance varies according to the species and the route of administration [20]. The LD₅₀ values of *H. acida* roots obtained in mice show that they vary according to the route of administration. Variations in LD₅₀ depending on the route of administration and the species

have already been reported with the lyophilized aqueous extract of *Tanacetum vulgare* [21]. Changes in body weight have been used as an indicator of adverse effects of drugs, chemicals and bioactive substances [22].

Since no significant changes in body weight were observed in rats in the treated groups compared to the control after daily treatment for 60 days, it is suggested that oral administration of AEHA has no effect on the normal growth of rats. Loss of appetite often leads to weight loss due to disturbances in carbohydrate, protein or fat metabolism [23]. Similarly, no significant changes in vital organ weights have been observed. Relative organ weights are considered a relatively sensitive indicator in toxicity studies [24].

At the hematological level, an increase in white blood cell count was observed in animals at different treatment doses on day 30 of AEHA treatment. This could be the result of the rats' response to the subchronic toxicity of the extract [25]. It could also be a stimulation of the non-specific immune defence by the plant extract. Indeed, the tannins present in this extract have immunostimulant activities [26]. Other authors have observed similar results. This is the case of Gupta et al. with the aqueous extract of *Clerodendrum phlomidis* leaves [27].

Glucose determination after 60 days of treatment with AEHA revealed a significant decrease in its concentration at 500 mg/kg BW to in males. This result could be related to the alkaloids present in the plant extract. Indeed, alkaloids have hypoglycemic properties [28]. This blood glucose lowering activity is in agreement with the results obtained by Adisa et al. [29]. A similar result was obtained by Gupta et al. with the aqueous extract of *C. phlomidis* leaves [28]. The increase in blood glucose levels induced by the aqueous extract at the dose of 1000 mg/kg BW could be explained by an inhibition of insulin production via the β cells of the islets of Langerhans by its bioactive compounds constituting AEHA. These bioactive substances could also stimulate the production of glucagon, adrenaline and glucocorticoids, which are hyperglycemic hormones at the origin of the phenomenon of neoglucogenesis [30].

There was an increase in triglyceride levels after 60 days of treatment with different doses in females compared to controls. This result could be explained by the richness of the extract of this plant in chemical compounds such as alkaloids. Indeed, these compounds have the capacity to positively influence the cardiovascular system by reducing, for example, body fat [31]. These results corroborate the work of Gupta et al. who found an increase in the level of this parameter with the aqueous extract of *C. phlomidis* leaves [27]. In males, however, there was no significant variation in this parameter in the experiment. These results are similar to those obtained by Bleu et al. who after administration of *Passiflora foetida* extract observed no significant variation in serum triglycerid concentration [32]. For cholesterol, there was a significant decrease in its blood level on day 60 of treatment in males at 1000 mg/kg BW compared to the control. This decrease in cholesterol levels indicates that AEHA has a hypolipidemic property [33]. This result is in agreement with that obtained by Bleu et al. [32]. Indeed, these authors administered a dose of 800 mg/kg BW of aqueous extract of *P. foetida* to rats and observed a decrease in blood cholesterol level.

Histopathological measurement have not been discussed

5. CONCLUSION

The aqueous extract of *Hymenocardia acida* roots is toxic by intraperitoneal administration and non-toxic by oral administration in single dose. However, oral administration of aqueous extract of *Hymenocardia acida* roots for several days, also revealed that this plant could

Comment [G6]: In the higher dose of AEHA does not contain higher alkaloids? Please explain. Thank you

have blood sugar lowering, non-specific immunity stimulating, cardiovascular protective, hepatoprotective and kidney protective effects.

CONSENT

It is not applicable.

ETHICAL APPROVAL

PLEASE ADD THE DECREE OF ETHICAL APPROVAL

Comment [G7]: please write and explain in the discussion, from which results it can be concluded that there are cardiovascular, hepatoprotective and protective kidney effects. Indeed, the subchronic toxicity test performed did not cause any changes in the histopathology of the kidneys and liver, but from that fact, can it be concluded that it has a protective effect? please kindly make a brief conclusion based only from the current result. Thank you

Comment [G8]: Please add the Ethical approval

REFERENCES

1. WHO. Guidelines for Assessing Quality of Herbal Medicines With Reference to Contaminants and Residues. World Health Organization, Geneva. 2007; 105 p. <https://apps.who.int/iris/handle/10665/43510>
2. Ukwuani AN, Abubakar MG, Hassan SW, Agaie BM. Toxicological studies of hydromethanolic leaves extract of *Grewia crenata*. International Journal of Pharmaceutical Science and Drug Research. 2012; 4: 245–249.
3. Arbonnier M. Trees, shrubs and lianas of West African dry zones. CIRAD, Margraf Publishers GmbH, MNHN, Paris, France. 2004; 573 pp.
4. Turiaux L. Tanins végétaux du Katanga. Bull. Agr.Congo belge. 1943 ; 33, 245-54, 1942 et 34, 160. DOI : <https://doi.org/10.4000/chs.1292>
5. Koné WM, Kamanzi AK, Traoré D, Bruno B.. Anthelmintic activity of medicinal plants used in northern Côte d'Ivoire against intestinal helminthiasis. Pharmaceutical Biology. 2005 ; 43(1): 72–78. DOI: <https://doi.org/10.1080/13880200590903408>
6. Sofidiya MO, Odukoya, OA, Familoni OB, Inya-Agha SI. Free radical scavenging activity of some Nigerian medicinal plant extracts. Pakistan Journal of Biological Sciences. 2009; 9 (8):1438–1441. DOI : 10.3923/pjbs.2006.1438.1441
7. Olotu NP, Ibrahim H, Ilyas N, Ajima U, Olotu AI. Depistage phytochimique et etude analgesiques de l'écorce de la racine de *Hymenocardia acida* Tul. (Euphorbiaceae). International Journal of Drug Developpement et Research. 2011; 3,219-223.
8. Miller LC, Tainter MC. Estimation of LD50 and its error by means of logarithmic probit graph paper. Proc. Soc. Exp. Boil. Med. 1944; 57: 261-264. DOI: <https://doi.org/10.3181/00379727-57-14776>
9. OCDE. Ligne directrice de l'OCDE pour les essais de produits chimiques : Étude de toxicité orale à dose répétée pendant 90 jours sur les rongeurs. OCDE 408; 2018: 16p. DOI: <https://doi.org/10.1787/20745788>
10. Dingenon B, Ferry JP, Rouillet A. Automatic essay of blood sugar by Trinder's method., Ann. Biol. Clin. 1975; 33: 3-13.
11. Young DS, Pestaner L, Gibber man V. Effects of drugs on clinical laboratory test. Clin. Chem., 1975; 21: ID-432D. PMID: 1091375
12. Allain CC, Poom LS, Chan CS, Richmond WS, Fu PC. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974; 20: 470-475. PMID : 4818200
13. Kaplan LA, Szabo LL, Opherin EK. Clinical chemistry: interpretation and techniques, 3rd ed. Lea and Febiger, Philadelphia. 1988; 112-231.

14. Reitman SN, Frankel S. A colorimetric method for the determination of SGPT and SGPT. *Am. J. Clin. Pathol.* 1957; 25: 56- 62. DOI: 10.1093/ajcp/28.1.56
15. Henry RJ. *Clinical chemistry, principles and techniques*. Edition, Harper and Row. 1974; 543p.
16. Tietz NW. *Clinical Guide for Laboratory Tests*. W. B. Saunders Company: Philadelphia: USA. 1976; pp.723
17. Baker FJ, Silverton RE, Kilshaw D, Shannon R, Guthrie DL, Egglestone S, et al., Introduction to haematology. In *Introduction to Medical Laboratory Technology* (6th edn). Butterworths: London and Boston. 1985; 147-334.
18. Lamb GM. *Manual of Veterinary Laboratory Techniques in Kenya*. Ministry of livestock development/CIBAGEIGY, Basale: Switzerland, 1981; 93-107.
19. Diezi J. Toxicology: Basic principles and chemical impact. In *Pharmacology: Fundamental Principles and Practice*, Slatkine M. (ed). Academic Press: Genève. 1989; 33-44.
20. Morrisson JK, Quinton RM, Reinert. The Purpose and Value of LD50 Determination. *Modern Trends in Toxicology*. Butterworths: London. 1968; 1-17.
21. Lahlou S, Israili Z, Lyoussi B. Acute and chronic toxicity of a lyophilised aqueous extract of *Tanacetum vulgare* leaves in rodents. *J. Ethnopharmacol.* 2008; 117: 221-227. DOI: 10.1016/j.jep.2008.01.024
22. Theo S, Stirling D, Thomas S, Hoberman A, Kiorpes A, Khetani V. A 90day oral gavage toxicity study of D-methylphenidate and D,Lmethylphenidate in spragueDawley rats. *Toxicology.* 2002; 179:183-196. DOI: 10.1016/s0300-483x(02)00338-4
23. Fzeonwumelu JOC, Julius AK, Muhoho CN, Ajayi AM, Oyewale AA, Tanayen JK, et al., Biochemical and histological studies of aqueous extract of *Bidens pilosa* leaves from Ugandan Rift Valley in Rats. *British Journal of Pharmacology and Toxicology.* 2011; 2(6): 302–309.
24. Lullmann-Rauch R. *Histologie*. De Boeck Supérieur, Bruxelles, Belgique. 2008; 704p.
25. Kelly WR. *Veterinary clinic diagnosis*, Balliere Tindal, London. 1977; 271-282.
26. Feldman KS, Sahasrabudhe K, Smith RS, Scheuchenzuber WJ. Immunostimulation by plant polyphenols. A relationship between tumor necrosis factor α production and tannin structure. *Bioorg. Med. Chem. Lett.* 1999; 9(7): 985-990.
27. Gupta RK, Hussain T, Panigrahi G, Das A, Singh GN, Sweetey K, et al., Hepatoprotective effect of *Solanum xanthocarpum* fruit extract against CCl₄ induced acute liver toxicity in experimental animals. *Asian Pac. J. Trop. Med.* 2012; 4: 964-968. DOI: 10.1016/S1995-7645(11)60227-7
28. Kinghorn AD, Balandrin MF. Quinolizidine alkaloids of the Leguminosae: structural types, analysis, chemotaxonomy and biology activities. In: Pelletier W. S. (ed) *Alkaloids: chemical and biology perspectives*. Wiley, New York. 1984; 2: 105-148.
29. Adisa RA, Choudhary MI, Adewoye EO, Olorunsogo OO. Hypoglycaemic and biochemical properties of *Cnestis ferruginea*. *Afr. J. Trad. CAM.* 2010; 7(3): 185. 194.
30. Labrousse-Lhermine. *Diabète et corticoïdes*. Service de Diabétologie-maladie. Métabolique et Nutrition CHU Rangueil. 2008 ; 2p.
31. Schmeda-Hirschmann G, Rodriguez JA, Loyola JI, Astudillo L, Bastida J, Viladomat F, et al., Activity of Amaryllidaceae alkaloids on the blood pressure of normotensive rats. *Pharmacol. Comm.* 2000; 6: 309-312. DOI: <https://doi.org/10.1211/146080800128736105>

32. Bleu GM, Kouakou K, Zahoui OS, Touré A, Traoré F. Oral acute toxicity and estrogenic effects of the extracts of *Passiflora foetida* Linn.(Passifloraceae) leaves in female Wistar albino rats. *Ann Biol Res.* 2011; 3(9): 4609-4616. DOI: <http://dx.doi.org/10.4314/ijbcs.v5i5.1>
33. Nwozo SO, Kasuma TF, Oyinloye BE. *Eugenia caryophyllus* extract exerts hypocholesterolemic and antioxidant effects in high-cholesterol-fed rats. *Avicenna Journal of Medical Biochemistry.* 2015; 3(2):301-47. DOI: 10.17795/ajmb-30147

UNDER PEER REVIEW